All AbMole products are for research use only, cannot be used for human consumption.
CP-724714 is a potent and selective orally active HER-2 tyrosine kinase inhibitor under development for the treatment of advanced HER2-overexpressing cancers. CP-724714 has no appreciable activity toward EGFR (IC50 = 6400 nM) and is furthermore selective with respect to insulin receptor, IGF1R, PDGFRβ, VEGFR2, ABL, SRC and CDK.
| Cell Experiment | |
|---|---|
| Cell lines | ZR-75-30, HCC-1419, MDA-MB-175, BT-474, SKBR3, MDA-MB-361, UACC-812, T-47D, MDA-MB-453, MDA-MB-468, CAMA-1, MDA-MB-157, MCF-7, MDA-MB-435, ZR-75-1, BT-20, and MDA-MB-231cells line |
| Preparation method | Cell proliferation assays. Cells were seeded in duplicate at 5,000 to 10,000 per well in 24-well plates. The day after plating, CP-724,714 was added by titrating over six or more dilutions from 10 μmol/L down. Control wells without drug were seeded as well. Cells were grown for 6 to 7 days, at which time surviving cells were counted. After trypsinization, cells were placed in isotone solution and counted immediately using a Coulter Z2 particle counter (Beckman Coulter, Inc.). Growth inhibition was calculated [(1- experimental value / control value) × 100] for each concentration. Dose-response curves were repeated at least twice and averaged. IC50 values were calculated using Calcusyn Software (Biosoft). |
| Concentrations | 0~10 μ M |
| Incubation time | 6-7 days |
| Animal Experiment | |
|---|---|
| Animal models | Athymic female mice bearing human tumor cells (BT-474 and MDA-MB-453) xenograft models |
| Formulation | formulated in 0.5% methylcellulose |
| Dosages | 30 and 100mg/kg bid for 8-40 days |
| Administration | p.o. |
| Molecular Weight | 469.53 |
| Formula | C27H27N5O3 |
| CAS Number | 537705-08-1 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related EGFR/HER2 Products |
|---|
| AEE788
AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1. |
| Sapitinib (AZD8931)
AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively. |
| Afatinib
Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. |
| Erlotinib Hydrochloride
Erlotinib is an inhibitor of human EGFR tyrosine kinase (IC50 = 2 nM) and decreases EGFR autophosphorylation in tumor cells (IC50 = 20 nM). |
| Gefitinib
Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
